144 related articles for article (PubMed ID: 37995412)
21. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer.
Coates JT; Sun S; Leshchiner I; Thimmiah N; Martin EE; McLoughlin D; Danysh BP; Slowik K; Jacobs RA; Rhrissorrakrai K; Utro F; Levovitz C; Denault E; Walmsley CS; Kambadakone A; Stone JR; Isakoff SJ; Parida L; Juric D; Getz G; Bardia A; Ellisen LW
Cancer Discov; 2021 Oct; 11(10):2436-2445. PubMed ID: 34404686
[TBL] [Abstract][Full Text] [Related]
22. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil.
Carvalho FM; Bacchi LM; Pincerato KM; Van de Rijn M; Bacchi CE
BMC Womens Health; 2014 Aug; 14():102. PubMed ID: 25174527
[TBL] [Abstract][Full Text] [Related]
23. Loss of TROP2 and epithelial cell adhesion molecule expression is linked to grade progression in pTa but unrelated to disease outcome in pT2-4 urothelial bladder carcinomas.
Müller JH; Plage H; Elezkurtaj S; Mandelkow T; Huang Z; Lurati MCJ; Raedler JB; Debatin NF; Vettorazzi E; Samtleben H; Hofbauer S; Furlano K; Neymeyer J; Goranova I; Ralla B; Weinberger S; Horst D; Roßner F; Schallenberg S; Marx AH; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Lennartz M; Minner S; Simon R; Sauter G; Zecha H; Schlomm T; Bady E
Front Oncol; 2023; 13():1342367. PubMed ID: 38282671
[TBL] [Abstract][Full Text] [Related]
24. Trop2 Expression in Extramammary Paget's Disease and Normal Skin.
Ito T; Tanegashima K; Tanaka Y; Hashimoto H; Murata M; Oda Y; Kaku-Ito Y
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299325
[TBL] [Abstract][Full Text] [Related]
25. The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.
Shen M; Liu S; Stoyanova T
Am J Clin Exp Urol; 2021; 9(1):73-87. PubMed ID: 33816696
[TBL] [Abstract][Full Text] [Related]
26. Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metabolizer genotype.
Baek G; Jung L; Duong A; Gralow J
J Oncol Pharm Pract; 2022 Apr; 28(3):710-716. PubMed ID: 34761708
[TBL] [Abstract][Full Text] [Related]
27. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.
Schreiber AR; Andress M; Diamond JR
Expert Rev Anticancer Ther; 2021 Dec; 21(12):1303-1311. PubMed ID: 34651524
[No Abstract] [Full Text] [Related]
28. Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.
Bahlinger V; Branz A; Strissel PL; Strick R; Lange F; Geppert CI; Klümper N; Hölzel M; Wach S; Taubert H; Sikic D; Wullich B; Angeloni M; Ferrazzi F; Diehl L; Kovalenko M; Elboudwarej E; Jürgensmeier JM; Hartmann A; Eckstein M
Histopathology; 2024 Apr; 84(5):863-876. PubMed ID: 38196202
[TBL] [Abstract][Full Text] [Related]
29. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
Adams E; Wildiers H; Neven P; Punie K
ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
[TBL] [Abstract][Full Text] [Related]
30. Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
Seligson JM; Patron AM; Berger MJ; Harvey RD; Seligson ND
Ann Pharmacother; 2021 Jul; 55(7):921-931. PubMed ID: 33070624
[TBL] [Abstract][Full Text] [Related]
31. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.
Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y
J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285
[TBL] [Abstract][Full Text] [Related]
32. Trop2: Jack of All Trades, Master of None.
Lenárt S; Lenárt P; Šmarda J; Remšík J; Souček K; Beneš P
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33187148
[TBL] [Abstract][Full Text] [Related]
33. A literature review of the promising future of
Wen Y; Ouyang D; Zou Q; Chen Q; Luo N; He H; Anwar M; Yi W
Ann Transl Med; 2022 Dec; 10(24):1403. PubMed ID: 36660684
[TBL] [Abstract][Full Text] [Related]
34. Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan.
Zhao M; DiPeri TP; Raso MG; Zheng X; Rizvi YQ; Evans KW; Yang F; Akcakanat A; Roberto Estecio M; Tripathy D; Dumbrava EE; Damodaran S; Meric-Bernstam F
NPJ Breast Cancer; 2023 Aug; 9(1):66. PubMed ID: 37567892
[TBL] [Abstract][Full Text] [Related]
35. Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments.
Omori S; Muramatsu K; Kawata T; Miyawaki E; Miyawaki T; Mamesaya N; Kawamura T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Kenmotsu H; Naito T; Murakami H; Sugino T; Takahashi T
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2455-2463. PubMed ID: 34533624
[TBL] [Abstract][Full Text] [Related]
36. Molecular breast cancer subtypes and therapies in a public hospital of northeastern Brazil.
de Macêdo Andrade AC; Ferreira Júnior CA; Dantas Guimarães B; Pessoa Barros AW; Sarmento de Almeida G; Weller M
BMC Womens Health; 2014 Sep; 14():110. PubMed ID: 25216732
[TBL] [Abstract][Full Text] [Related]
37. Role of sacituzumab govitecan in solid tumors.
Veeraballi S; Khawar Z; Aslam HM; Muzaffar M
J Oncol Pharm Pract; 2022 Oct; 28(7):1617-1623. PubMed ID: 35404158
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas.
Gerhard R; Ricardo S; Albergaria A; Gomes M; Silva AR; Logullo ÂF; Cameselle-Teijeiro JF; Paredes J; Schmitt F
Breast; 2012 Jun; 21(3):354-60. PubMed ID: 22464177
[TBL] [Abstract][Full Text] [Related]
39. A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.
Bardia A; Hurvitz SA; Rugo HS; Brufsky A; Cortes J; Loibl S; Piccart M; Cowden J; Spears P; Carey LA
Future Oncol; 2021 Oct; 17(30):3911-3924. PubMed ID: 34467774
[TBL] [Abstract][Full Text] [Related]
40. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
